Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we...

Descripción completa

Detalles Bibliográficos
Autores principales: Notario, Lucía, Cucurull, Marc, Cerdà, Gabriela, Sanz, Carolina, Carcereny, Enric, Muñoz-Mármol, Ana, Hernández, Ainhoa, Domènech, Marta, Morán, Teresa, Sánchez-Céspedes, Montse, Costa, Marta, Mate, Jose-Luis, Esteve, Anna, Saigí, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616300/
https://www.ncbi.nlm.nih.gov/pubmed/37916173
http://dx.doi.org/10.3389/fonc.2023.1239000

Ejemplares similares

Ejemplares similares